Live | Norge | Sverige | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDX | FondForsinkede kurser. Sist oppdatert: lørdag 21. april
Oversikt
Kursliste
Indekser
Nyheter
Største handler
Tegningsretter
Historikk
Vinnere/tapere
Høy/lav

16/04-2018 07:00:13: (NANO) Nordic Nanovector Presents Preclinical Data at AACR 2018

Oslo, Norway, 16 April 2018

Nordic Nanovector ASA (OSE: NANO) announces that a poster reporting the anti
-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody,
177Lu-NNV003) in preclinical models of non-Hodgkin's lymphoma (NHL) was
presented yesterday at the American Association of Cancer Research (AACR) Annual
Meeting 2018 in Chicago, USA.  The company previously announced the publication
of the poster abstract (abstract 848) on 15 March 2018.

The poster was entitled "In vitro and in vivo evaluation of the beta-emitting
lutetium-177 labeled anti-CD37 antibody radionuclide conjugate 177Lu-NNV003 in
DLBCL, CLL and MCL models," and showed that:

In tumour cell lines:

. The unlabelled anti-CD37 antibody (NNV003) kills tumour cells mainly through
an immunological process called antibody dependent cellular cytotoxicity

. Humalutin® (177Lu-NNV003) was found to inhibit tumour cell growth.

In preclinical lymphoma models:

. Humalutin® has shown significant tumour uptake and demonstrated an anti-tumour
effect in all three NHL models (mantle cell lymphoma, diffuse large B-cell
lymphoma and chronic lymphocytic leukaemia).

The poster is available at www.nordicnanovector.com in the section Scientific
Publications.

-End-

For further information, please contact:

IR enquiries Malene Brondberg, VP Investor Relations and Corporate
Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the
treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial
unmet medical need, representing a growing market forecast to be worth nearly
USD 20 billion by 2024.

Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets.

The Company is also advancing a pipeline of ARCs and other immunotherapies for
multiple cancer indications.

Further information about the Company can be found at www.nordicnanove

Ekstern link: http://www.newsweb.no/index.jsp?messageId=448749

Nyheten er levert av OBI.


Utforming  |   Hjelp  |   Utskrift
Lokal tid i Norge: 21/04-2018 19:38:09. Ingen åpne markeder